Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
Oleg A LevadaAlexandra S TroyanIrina Y PinchukPublished in: BMC psychiatry (2020)
registered at ClinicalTrials.gov (NCT03187093). First posted on 14th June 2017.